MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status - Abstract

Department of Urology, University of California, Davis, CA.

School of Medicine and Cancer Center, Sacramento, California 95817, USA.

 

 

MiR-34a is a downstream effector of p53 that has been shown to target several molecules associated with cell cycle and cell survival pathways. As alterations in these pathways are frequent in muscle invasive transitional cell carcinoma of the bladder (MI-TCC), for example mutation or loss of p53 and Rb, the goal of this study was to determine whether manipulation of miR-34a expression levels could abrogate the effect of these alterations and sensitize bladder cancer cells to chemotherapy. We demonstrate that transfection of T24, TCCSUP and 5637 with pre-miR-34a followed by cisplatin treatment results in a dramatic reduction in clonogenic potential and induction of senescence compared to treatment with cisplatin alone. Molecular analyses identified Cdk6 and SIRT-1 as being targeted by miR-34a in MI-TCC cells, however, inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization. Analysis of 27 pre-neoadjuvant chemotherapy patient samples revealed many of the patients who subsequently did not respond to treatment (based on surgical resection post-chemotherapy and 5 year survival data) express lower levels of miR-34a, however, a statistically significant difference between the responder and non-responder groups was not observed (p=0.1174). Analysis of 8 sets of pre- and post-neoadjuvant chemotherapy patient samples determined miR-34a expression increased post-chemotherapy in only 2 of the 8 patients. The combined data indicate that elevation of miR-34a expression levels prior to chemotherapy would be of benefit to MI-TCC patients, particularly in a setting of low miR-34a expression.

Written by:
Vinall RL, Zripoll A, Wang S, Pan CX, Devere White RW.   Are you the author?

Reference: Int J Cancer. 2011 Jun 23. Epub ahead of print.
doi: 10.1002/ijc.26256

PubMed Abstract
PMID: 21702042

UroToday.com Bladder Cancer Section